FDA Clears Prelude's First-in-Class Oral KAT6A Degrader for Phase 1
PRLD has more than doubled off its 52-week low of $0.981.
Summary
Prelude Therapeutics received FDA clearance to begin a Phase 1 study of PRT13722, its first-in-class oral KAT6A selective degrader for HR+/HER2- breast cancer. Enrollment is expected to start in Q4 2026. This is a meaningful pipeline milestone for a $406M market cap company with a cash runway into 2028. The program targets a clinically validated mechanism with a differentiated selectivity profile that may improve safety and combinability versus dual KAT6A/B inhibitors. The company's Q2 2026 results showed a narrowed loss and extended runway, providing support for this clinical advancement.
At the time of this announcement, PRLD was trading at $5.40 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $406.2M. The 52-week trading range was $0.98 to $6.83. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.